Síndrome POPP: onicopaquidermoperiostite psoriásica POPP syndrome: Psoriatic onychopachydermoperiostitis.

Síndrome POPP: onicopaquidermoperiostite psoriásica [POPP syndrome: Psoriatic onychopachydermoperiostitis]. Dermatol Online J. 2013;19(4):18175 Authors: Romiti R, Santos D, Carvalho J, Arnone M, Takahashi MD Abstract Psoriatic onychopachydermoperiostitis (POPP) syndrome characterizes a clinical variant of psoriatic arthritis originally described by Fournie et al in 1989. Both great toes are generally affected presenting with nail changes, painful swelling of the soft tissue close to the distal phalanx as well as specific radiologic changes such as periosteal reaction and bone erosions of the distal phalanges. Joint involvement is characteristically absent and classic psoriatic lesions may be associated. Painful symptoms may lead to severe functional and quality of life impairment. Traditional systemic treatment is generally frustrating. Here we report a female patient presenting POPP syndrome refractory to traditional systemic treatments and adalimumab, further presenting a favorable response to treatment with etanercept. PMID: 24021366 [PubMed - in process]
Source: Dermatol Online J - Category: Dermatology Authors: Tags: Dermatol Online J Source Type: research

Related Links:

ConclusionsDisease burden in patients with PsA or axSpA was comparable to or greater than that in patients with RA on the basis of common patient-reported outcome measures but appeared lower when assessed using RA disease activity measures, suggesting that disease-specific approaches to care are needed to optimize disease management.FundingThis study was sponsored by Corrona, LLC, and financial support was provided by Novartis. The Rapid Service Fee was funded by Novartis.Plain Language SummaryPlain language summary available for this article.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research
This study compared real-world treatment patterns and healthcare costs among biologic-naive patients with PsA initiating apremilast or biologics. Methods: A retrospective cohort study was conducted using the Optum Clinformatics™ claims database. The study included biologic-naive patients with PsA who initiated treatment with apremilast or a biologic between January 1, 2014, and December 31, 2015. Propensity score matching was used to adjust for selection bias. Treatment persistence/adherence and all-cause healthcare costs were evaluated. Cost differences were determined using Wilcoxon rank-sum tests. Results: In all,...
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Publication date: Available online 12 September 2019Source: Joint Bone SpineAuthor(s): Thomas El Jammal, Mathieu Gerfaud-Valentin, Pascal Sève, Yvan JamillouxAbstractThree Janus kinase (JAK) inhibitors, ruxolitinib, tofacitinib, and baricitinib, are currently approved by the FDA/EMA for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative rectocolitis. The inhibition of JAK/STAT signaling by these small molecules, downstream of several cytokine receptors, results in lower pro-inflammatory gene expression. Given the cytokine profiles observed in rheumatologic diseases, most of the recent therape...
Source: Joint Bone Spine - Category: Orthopaedics Source Type: research
If TNF inhibitors are initiated in the early stages of psoriatic arthritis, this could potentially modulate disease and therefore allow us to discontinue the TNF inhibitor after achieving remission.
Source: Arthritis Research and Therapy - Category: Rheumatology Authors: Tags: Research article Source Type: research
In what ways might DMARD treatment impact bone structure and strength in patients with psoriatic arthritis?Arthritis Research &Therapy
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
In this study, SUA, CRP, creatinine, MCP-1, IFN- α2, IFN-γ, Il-1β, IL-6, IL-8, IL-10, IL-12, IL-17a, IL-18, IL-23, IL-33, TNF-α, and allantoin levels were measured prior to and after 3 months of TNFis treatment in patients with SARDs. The values obtained in the biochemical assays were then tested for associations with the patients’ demograp hic and disease-related data. A total of 128 patients (rheumatoid arthritis,n = 44; ankylosing spondylitis,n = 45; psoriatic arthritis,n = 23; and adults with juvenile idiopathic arthritis,n = 16) ...
Source: Rheumatology International - Category: Rheumatology Source Type: research
Conclusion: These data showed the early biological experience in Brazil that were associated with ADRs, withdrawals due to ADRs and SAEs. The quantification of adverse effects (serious or nonserious) considering close monitoring and patients’ perceptions are increasingly important for future decision-making.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Abstract Psoriasis affects 1-3% of the population and up to 1/3 of psoriasis patients have underlying psoriatic arthritis (PsA)1 . Non-specific musculoskeletal complaints are even higher, being around 50%2 . Detecting early signs of PsA and early treatments are crucial to improve the outcomes to prevent progressive, damaging arthritis3 . Due to the high frequency of non-specific pain in psoriasis, it is not possible for every psoriasis patient with joint pain to be assessed by a rheumatologist. PMID: 31505032 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
Publication date: Available online 7 September 2019Source: Pharmacological ResearchAuthor(s): Rossella Talotta, Fabiola Atzeni, Piercarlo Sarzi-PuttiniAbstractThe pathogenesis of psoriatic arthritis (PSA) is still a matter of debate. A favourable genetic background is interwoven with environmental triggering factors in a complex network. Shared antigens and the recirculation of immune cells may account for the clinical manifestations, involving both cutaneous and articular sites. A favourable genetic background has been demonstrated in many genomic and proteomic studies, being associated to polymorphic variants of the gene...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 6 September 2019Source: Best Practice &Research Clinical RheumatologyAuthor(s): Martijn A.H. Oude Voshaar, Mart A.F.J. van de LaarAbstractPatient-reported outcome measures are commonly used in the assessment of patients with musculoskeletal diseases. The present review provides an overview of historic and recent developments, including core set recommendations for assessing patient-reported outcomes in patients with fibromyalgia, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. The evidence supporting commonly used patient-reported outcomes measur...
Source: Best Practice and Research Clinical Rheumatology - Category: Rheumatology Source Type: research
More News: Arthritis | Dermatology | Enbrel | Humira | Psoriatic Arthritis | Rheumatology